284 related articles for article (PubMed ID: 28220370)
1. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension.
Buda V; Andor M; Cristescu C; Voicu M; Cochera F; Tuduce P; Petrescu L; Tomescu MC
Ir J Med Sci; 2017 Aug; 186(3):621-629. PubMed ID: 28220370
[TBL] [Abstract][Full Text] [Related]
2. The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients.
Unlu M; Karaman M; Ay SA; Balta S; Cakar M; Demirkol S; Celik T; Arslan E; Demirbas S; Turker T; Yaman H; Bulucu F; Sağlam K
Clin Exp Hypertens; 2013; 35(6):418-23. PubMed ID: 23148500
[TBL] [Abstract][Full Text] [Related]
3. Candesartan effect on inflammation in hypertension.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Hypertens Res; 2010 Mar; 33(3):209-13. PubMed ID: 20075928
[TBL] [Abstract][Full Text] [Related]
4. The effect of valsartan and nebivolol treatment on ADMA and pentraxin-3 levels in hypertensive patients.
Parlak A; Iyisoy A; Aydogan U; Cakir E; Saglam K
Med Hypotheses; 2012 Sep; 79(3):294-8. PubMed ID: 22698960
[TBL] [Abstract][Full Text] [Related]
5. Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.
Sakamoto M; Suzuki H; Hayashi T; Iuchi H; Isaka T; Sakamoto N; Kayama Y; Tojo K; Yoshimura M; Utsunomiya K
Cardiovasc Diabetol; 2012 Oct; 11():118. PubMed ID: 23034088
[TBL] [Abstract][Full Text] [Related]
6. Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication.
Tomiyama H; Yambe M; Yamada J; Motobe K; Koji Y; Yoshida M; Shiina K; Yamashina A
J Hypertens; 2007 Apr; 25(4):883-9. PubMed ID: 17351383
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
Yilmaz MI; Carrero JJ; Martín-Ventura JL; Sonmez A; Saglam M; Celik T; Yaman H; Yenicesu M; Eyileten T; Moreno JA; Egido J; Blanco-Colio LM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1174-81. PubMed ID: 20430947
[TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients.
Ashcheulova T; Gerasimchuk N; Kovalyova O; Honchar O
Rom J Intern Med; 2018 Dec; 56(4):257-264. PubMed ID: 30521476
[TBL] [Abstract][Full Text] [Related]
9. Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Skoczylas A; Piecha G; Więcek A
Pol Arch Med Wewn; 2016 Apr; 126(4):243-53. PubMed ID: 27129086
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of plasma pentraxin 3 levels for predicting cardiac troponin elevation after percutaneous coronary intervention.
Wang Z; Sato A; Akiyama D; Kimura T; Tajiri K; Hoshi T; Sakai S; Koike A; Miyauchi T; Aonuma K
Life Sci; 2014 Jan; 95(1):40-4. PubMed ID: 24333560
[TBL] [Abstract][Full Text] [Related]
11. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
Koh KK; Ahn JY; Han SH; Kim DS; Jin DK; Kim HS; Shin MS; Ahn TH; Choi IS; Shin EK
J Am Coll Cardiol; 2003 Sep; 42(5):905-10. PubMed ID: 12957441
[TBL] [Abstract][Full Text] [Related]
12. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension.
Dohi Y; Ohashi M; Sugiyama M; Takase H; Sato K; Ueda R
Hypertens Res; 2003 Sep; 26(9):691-7. PubMed ID: 14620923
[TBL] [Abstract][Full Text] [Related]
13. A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension.
Zhao D; Liu H; Dong P
Clin Exp Hypertens; 2019; 41(1):75-79. PubMed ID: 29589977
[TBL] [Abstract][Full Text] [Related]
14. Pentraxin 3 as a biomarker of local inflammatory response to vascular injury in systemic lupus erythematosus.
Cieślik P; Hrycek A
Autoimmunity; 2015 Jun; 48(4):242-50. PubMed ID: 25401491
[TBL] [Abstract][Full Text] [Related]
15. Relationships between plasma pentraxin 3 levels and inflammation markers patients with tunneled permanent catheter in hemodialysis.
Yigit IP; Dogukan A; Taskapan H; Comert M; Ilhan N; Ulu R; Aygen B
J Vasc Access; 2015; 16(5):377-81. PubMed ID: 26070095
[TBL] [Abstract][Full Text] [Related]
16. Pentraxin-3 as a local inflammatory marker in chronic spontaneous urticaria.
Kasperska-Zajac A; Grzanka A; Misiolek M; Mazur B; Machura E
Cytokine; 2015 Dec; 76(2):566-568. PubMed ID: 25982553
[TBL] [Abstract][Full Text] [Related]
17. Pentraxin-3 concentrations in stable coronary artery disease depend on the clinical presentation.
Hudzik B; Danikiewicz A; Szkodzinski J; Polonski L; Zubelewicz-Szkodzinska B
Eur Cytokine Netw; 2014; 25(3):41-5. PubMed ID: 25373851
[TBL] [Abstract][Full Text] [Related]
18. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
19. Systemic pentraxin-3 levels reflect vascular enhancement and progression in Takayasu arteritis.
Tombetti E; Di Chio MC; Sartorelli S; Papa M; Salerno A; Bottazzi B; Bozzolo EP; Greco M; Rovere-Querini P; Baldissera E; Del Maschio A; Mantovani A; De Cobelli F; Sabbadini MG; Manfredi AA
Arthritis Res Ther; 2014 Nov; 16(6):479. PubMed ID: 25394473
[TBL] [Abstract][Full Text] [Related]
20. Plasma Pentraxin 3, but not high-sensitivity C-reactive protein, is a useful inflammatory biomarker for predicting cognitive impairment in elderly hypertensive patients.
Yano Y; Matsuda S; Hatakeyama K; Sato Y; Imamura T; Shimada K; Kodama T; Kario K; Asada Y
J Gerontol A Biol Sci Med Sci; 2010 May; 65(5):547-52. PubMed ID: 20203097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
